Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients with Large Vessel Occlusion (ETERNAL-LVO)
Extending the Time Window for Tenecteplase by Effective Reperfusion of PeNumbrAL Tissue in Patients with Large Vessel Occlusion
Sponsor: Professor Mark Parsons
Terminated
Loss of equipoise in the 0-4.5h population which comprised the majority of ETERNAL-LVO trial recruitment due to publication of other trials demonstrating efficacy of tenecteplase vs alteplase in the 0-4.5h time window.
Other Ischemic Stroke trials with similar outcome
A PHASE3 clinical study on Ischemic Stroke, this trial is terminated or withdrawn. The trial is conducted by Professor Mark Parsons and has accumulated 8 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Feb 2025 — Sep 2025 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Sep 2021 — Jul 2024 [monthly]
Recruiting PHASE3
▶ Show 3 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Aug 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Professor Mark Parsons
- University of Melbourne
For direct contact, visit the study record on ClinicalTrials.gov .